A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease.

Trial Profile

A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms BETTER
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 May 2012 Actual patient number is 51 as reported by ClinicalTrials.gov.
    • 15 May 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.
    • 15 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top